secwatch.observer — SEC 8-K summary
======================================

Issuer:     BAXTER INTERNATIONAL INC (BAX)
CIK:        0000010456
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001628280-23-013356
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Baxter Q1 revenue $3.65B (-2%); adjusted EPS $0.59 beats guidance
-----------------------------------------------------------------

- Q1 revenue $3.65B, -2% reported, +2% constant currency, exceeding prior guidance.
- GAAP EPS $0.09; adjusted EPS $0.59, down 37% YoY but above guidance.
- Full-year 2023 guidance: GAAP EPS $1.16-$1.31; adjusted $2.85-$3.00; sales growth 1-2% reported.
- Q2 guidance: sales growth 1-2% reported; adjusted EPS $0.59-$0.61.
- Kidney Care spinoff expected by July 2024 or earlier; new operating model into 4 segments underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10456/000162828023013356/0001628280-23-013356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10456/000162828023013356/bax-20230427.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-013356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer